BLTE vs CGON
Side-by-side comparison of price performance, valuation, growth, profitability, analyst targets and technical trend.
BLTE · Belite Bio$154.19 ▲ 7.68%
CGON · CG Oncology$75.99 ▲ 17.27%
One year, rebased to 100
Each line starts at 100 so growth is directly comparable
- BLTE +31.4%
- CGON +88.9%
Head to head
| Metric | BLTE | CGON |
|---|---|---|
| Price | $154.19 | $75.99 |
| Change today | ▲ 7.68% | ▲ 17.27% |
| Market cap | $6.21B | $6.74B |
| Return, 3 months | -7.8% | -0.7% |
| Return, year to date | -3.6% | +83.0% |
| Return, 1 year | +36.2% | +91.5% |
| P/E (TTM) | – | – |
| P/B | 8.0 | 6.8 |
| P/E percentile vs own 5y | 44th | 64th |
| Dividend yield | – | – |
| Revenue growth (YoY, latest qtr) | – | – |
| Net profit growth (YoY) | -74.1% | -90.8% |
| Gross margin | – | -85.2% |
| Operating margin | – | -4,056.2% |
| Net margin | – | -3,602.7% |
| Return on equity | -22.1% | -26.4% |
| Analyst target vs. price | +52.4% | +21.8% |
| Analyst buy share | 100% | 100% |
| RSI (14) | 51 | 68 |
| 30-day volatility | 49.4% | 63.7% |
| Max drawdown, 1 year | -29.1% | -27.4% |
| Trend read | Leaning bullish | Strong uptrend |
| Analyst consensus | Buy | Buy |
Green cells mark the best value in each row where "better" is clear-cut (lower P/E, higher margin). That is a reading of the numbers, not a recommendation. Financials are in each company's reporting currency.
What the numbers say
- CGON is the largest of the group by market value.
- CGON has returned the most over the past year.
- BLTE has been the calmest stock over the last 30 days.